I usually avoid commenting on current events occurring in the field of regenerative medicine, primarily because I can’t keep up! In this case, I believe the recent publication by Amariglio et al, has FDA regulatory implications for the clinical development of therapies based on stem cells. The under-lined portion of the title of the publication says it all:
“Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient”